Holen Sie sich die Stockscreener-App
66.54
0.10%
0.00
Schlusskurs vom Vortag:
$66.54
Offen:
$66.625
24-Stunden-Volumen:
1.72M
Relative Volume:
0.64
Marktkapitalisierung:
$12.76B
Einnahmen:
$353.78M
Nettoeinkommen (Verlust:
$-805.69M
KGV:
-15.89
EPS:
-4.1869
Netto-Cashflow:
$-597.61M
1W Leistung:
-5.82%
1M Leistung:
-14.40%
6M Leistung:
+36.29%
1J Leistung:
+99.12%
1-Tages-Spanne:
$64.33
$66.75
1-Wochen-Bereich:
$63.50
$71.51
52-Wochen-Spanne:
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
66.58 | 12.75B | 353.78M | -805.69M | -597.61M | -4.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.64 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.66 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
769.31 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.48 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
320.34 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Pharma Earnings Call Signals Profitable Pivot - TipRanks
BridgeBio Pharma (BBIO) Analyst Rating Update: Oppenheimer Lowers Price Target | BBIO Stock News - GuruFocus
BridgeBio Pharma (BBIO): Today's Analyst Rating Update | BBIO St - GuruFocus
BridgeBio Pharma (BBIO) Receives Analyst Rating and Price Target Update | BBIO Stock News - GuruFocus
BridgeBio Pharma (BBIO): Evercore ISI Group Raises Price Target to $125 | BBIO Stock News - GuruFocus
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q4 2025 Earnings Call Transcript - Insider Monkey
BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside - TipRanks
BridgeBio Pharma Reports Narrower Net Loss For Q4, Revenue Zooms On Attruby Sales - Nasdaq
BridgeBio Pharma earnings missed by $0.28, revenue topped estimates - Investing.com Australia
Decoding BridgeBio Pharma Inc (BBIO): A Strategic SWOT Insight - GuruFocus
BridgeBio Pharma (BBIO) Projects Strong Cash Flow by 2028 - GuruFocus
BridgeBio Pharma, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript - AOL.com
BridgeBio Pharma Q4 Earnings Call Highlights - Yahoo Finance
BridgeBio rises on revenue beat despite wider loss - Investing.com South Africa
BridgeBio (BBIO) Exceeds Revenue Expectations in Q4 - GuruFocus
BridgeBio Pharma: Fourth Quarter Financial Highlights - Bitget
BridgeBio Pharma: Q4 Earnings Snapshot - marketscreener.com
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates - The Manila Times
BridgeBio Pharma Earnings Review: Q4 Summary - Benzinga
Three late-stage drug wins move BridgeBio toward six genetic treatments - Stock Titan
BridgeBio Pharma, Inc. announced that its investigational drug Encaleret for ADH1 (Autosomal Dominant Hypocalcemia Type 1) achieved positive results in the Phase 3 CALIBRATE clinical trial. - Bitget
BridgeBio Pharma (BBIO) Investor Outlook: Exploring a 44% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
Insights Ahead: BridgeBio Pharma's Quarterly Earnings - Benzinga
BridgeBio to Participate in March Investor Conferences - The Manila Times
Blue Owl, Genuine Parts, And Okta Are Among Top 10 Large Cap Losers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio? - Benzinga
BridgeBio Pharma, Inc. $BBIO Shares Sold by HighTower Advisors LLC - MarketBeat
BridgeBio Pharma Inc (BBIO) Stock Price, Quote, News & History - Benzinga
BridgeBio Pharma Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
BridgeBio (BBIO) Shares Dip After UBS Summit Withdrawal - GuruFocus
16,893 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by L & S Advisors Inc - MarketBeat
Skandinaviska Enskilda Banken AB publ Has $7.74 Million Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Randal Scott Sells 10,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock - Defense World
Bank of America Securities Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
Oppenheimer & Co. Inc. Takes $407,000 Position in BridgeBio Pharma, Inc. $BBIO - Defense World
HC Wainwright Boosts Earnings Estimates for BridgeBio Pharma - MarketBeat
NEOS Investment Management LLC Has $5.02 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 510 Shares - MarketBeat
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CFO Sells 13,600 Shares of Stock - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Director Randal Scott Sells 10,000 Shares - MarketBeat
BridgeBio Pharma director Scott sells $754k in BBIO stock By Investing.com - Investing.com Australia
BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock By Investing.com - Investing.com Canada
BridgeBio Pharma CAO Apuli sells $37898 in BBIO stock - Investing.com
BridgeBio Pharma director Scott sells $754k in BBIO stock - Investing.com
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Yahoo Finance
BridgeBio earnings up next: Can pipeline wins fuel growth? By Investing.com - Investing.com Canada
BridgeBio earnings up next: Can pipeline wins fuel growth? - Investing.com Australia
BridgeBio Pharma, Inc. $BBIO Shares Sold by Readystate Asset Management LP - MarketBeat
Cibc World Market Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact - Insider Monkey
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
0.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):